Ochre Bio Taiwan Ltd
Update：2023/06/12
Industries
Main Industry
Health Care
Main Product/Service
Ochre Bio’s key technology pillars include a Human Discovery Platform (combining patient liver data with gene perturbation atlases), a Human Validation Platform (using perfused livers, diseased tissue slices, and primary cells), and an RNA Therapeutics Pl
Founded Year
2021
Unified Business No.
90531036
Status
Active
Number of Employees
8
Total Paid-in
Capital
0 (NT$)
Location of Company
Taiwan
, Taipei City
Year of establishment, company status, responsible person, paid-in capital amount, and registered address are sourced from the "Commerce Industrial Services Portal, Department of Commerce, MOE. Exit status refers to various situations, including emerging stock exchanges (e.g., potential exits), mergers and acquisitions (M&A), and IPOs. The overseas development countries are collected through information provided by startups themselves and the information filled in when registering for matchmaking events. Therefore, the information cannot be updated in real time. If you wish to make corrections, please email findit.tier@gmail.com. Thank you.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
Ochre Bio is a biotech company focused on chronic liver disease therapeutics, aiming to eliminate the need for liver transplants. Their platform integrates human liver data, AI‑driven genomics, and in‑house validation using perfused human liver tissue to
Corporate Video
